Published in Cancer Cell on February 01, 2007
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol (2013) 2.46
Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Drosophila neuroblast asymmetric divisions: cell cycle regulators, asymmetric protein localization, and tumorigenesis. J Cell Biol (2008) 1.70
Cell cycle-dependent ciliogenesis and cancer. Cancer Res (2008) 1.54
Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol (2008) 1.44
Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res (2010) 1.31
The aurora kinases in cell cycle and leukemia. Oncogene (2014) 1.20
p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle (2012) 1.15
Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet (2009) 1.06
Hipk2 cooperates with p53 to suppress γ-ray radiation-induced mouse thymic lymphoma. Oncogene (2011) 1.03
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia (2009) 0.98
Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med (2013) 0.97
A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2. J Biol Chem (2009) 0.95
Primary cilia: highly sophisticated biological sensors. Sensors (Basel) (2009) 0.95
Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle (2012) 0.94
A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors. Cancer Res (2009) 0.93
Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells. Cell Cycle (2013) 0.92
Cis lethal genetic interactions attenuate and alter p53 tumorigenesis. Proc Natl Acad Sci U S A (2010) 0.88
Transcriptional control of mitosis: deregulation and cancer. Front Endocrinol (Lausanne) (2015) 0.87
G Protein-coupled receptor kinase 5 is localized to centrosomes and regulates cell cycle progression. J Biol Chem (2012) 0.85
Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget (2015) 0.84
Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells. Cancer Chemother Pharmacol (2008) 0.84
Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood (2011) 0.81
Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53. Cancer Biol Ther (2011) 0.81
p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability. Cell Cycle (2012) 0.80
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget (2016) 0.76
TP53/p53 alterations and Aurora A expression in progressor and non-progressor colectomies from patients with longstanding ulcerative colitis. Int J Mol Med (2014) 0.76
Genetic background influences loss of heterozygosity patterns in radiation-induced mouse thymic lymphoma. J Nat Sci (2015) 0.75
p53, transcriptional, and drug sensitivity: fresh perspectives on an old activity. Cell Cycle (2010) 0.75
Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer. Front Oncol (2016) 0.75
Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol (2016) 0.75
The RP-p53-Mdm2 pathway: a new link to genetic integrity? Cell Cycle (2010) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Surfing the p53 network. Nature (2000) 35.36
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Genomic analysis of regulatory network dynamics reveals large topological changes. Nature (2004) 9.32
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 8.91
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39
Global organization of metabolic fluxes in the bacterium Escherichia coli. Nature (2004) 7.18
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature (2005) 6.86
Aneuploidy and cancer. Nature (2004) 5.61
Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 5.56
Abnormal centrosome amplification in the absence of p53. Science (1996) 4.60
Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J (2002) 4.54
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet (2000) 4.13
Evolutionary conservation of motif constituents in the yeast protein interaction network. Nat Genet (2003) 4.04
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene (1993) 4.03
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene (1997) 3.08
Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev (2004) 2.96
The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev (2003) 2.64
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet (1994) 2.61
P53 and radiation responses. Oncogene (2003) 2.52
Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res (1999) 2.28
P53 and prognosis: new insights and further complexity. Cell (2005) 2.28
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Imatinib as a paradigm of targeted therapies. Adv Cancer Res (2004) 2.11
Directing cell division during development. Science (1989) 2.08
p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03
Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol (2005) 1.77
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res (1995) 1.42
Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv (1997) 1.41
Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci (2006) 1.34
Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J (2002) 1.25
Mitosis in the Drosophila embryo--in and out of control. Trends Genet (1991) 1.16
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev (2003) 1.09
Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res (2005) 1.00
Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice. Oncogene (2005) 0.95
Calculated resistance in cancer. Nat Med (2005) 0.92
Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress. Oncogene (1999) 0.87
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
International network of cancer genome projects. Nature (2010) 20.35
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Sequencing of 50 human exomes reveals adaptation to high altitude. Science (2010) 11.27
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 11.24
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet (2010) 5.44
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell (2012) 5.15
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
In situ analyses of genome instability in breast cancer. Nat Genet (2004) 4.32
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Giant magnetoresistance in organic spin-valves. Nature (2004) 3.72
Restriction of receptor movement alters cellular response: physical force sensing by EphA2. Science (2010) 3.72
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 3.52
Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell (2009) 3.50
Nuclear envelope budding enables large ribonucleoprotein particle export during synaptic Wnt signaling. Cell (2012) 3.50
miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med (2010) 3.50
Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am J Hum Genet (2011) 3.43
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A (2010) 3.41
Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res (2010) 3.40
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell (2009) 3.34
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A (2010) 3.03
Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A (2007) 3.02
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Structural insights into the mechanism of abscisic acid signaling by PYL proteins. Nat Struct Mol Biol (2009) 2.94
A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol (2010) 2.93
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis (2005) 2.82
Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol (2004) 2.75
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology (2010) 2.51
Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J Neurosci (2005) 2.46
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation. Neuron (2011) 2.42
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Stem-cell hierarchy in skin cancer. Nat Rev Cancer (2003) 2.36
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat (2009) 2.34
Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod (2009) 2.34
Efficient and robust feature extraction by maximum margin criterion. IEEE Trans Neural Netw (2006) 2.32
Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31
Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. Gene (2006) 2.31
In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) (2009) 2.30
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A (2011) 2.22
Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther (2006) 2.15
Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol (2011) 2.15
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A (2011) 2.14
MSOAR: a high-throughput ortholog assignment system based on genome rearrangement. J Comput Biol (2007) 2.14
The Mg-chelatase H subunit of Arabidopsis antagonizes a group of WRKY transcription repressors to relieve ABA-responsive genes of inhibition. Plant Cell (2010) 2.13
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab (2010) 2.09